We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Activity Predicts Progression of Autoimmune Disease

By LabMedica International staff writers
Posted on 04 Jan 2017
A new diagnostic tool has been designed for a rare and deadly autoimmune disease called systemic sclerosis that affects the skin and internal organs and the disease affects about 100,000 people in the USA.

The cause of systemic sclerosis (SSc) is unknown, and there are no drugs approved for treating it. Many patients are given drugs that are approved for use in other diseases, but each drug is clinically effective in only a fraction of patients. To find out if a patient is responding to treatment, clinicians use a test called the modified Rodnan skin score (mRSS), in which a doctor pinches the skin to see how thick it is.

Scientists at the Stanford University School of Medicine (CA, USA) and six other institutions performed an integrated, multicohort analysis of SSc transcriptome data across seven datasets from six centers composed of 515 samples. Using 158 skin samples from SSc patients and healthy controls recruited at two centers as a discovery cohort, they identified a 415-gene expression signature specific for SSc, and validated its ability to distinguish SSc patients from healthy controls in an additional 357 skin samples from five independent cohorts.

The investigators defined the SSc skin severity score (4S). In every SSc cohort of skin biopsy samples analyzed in the study, 4S correlated significantly with mRSS, allowing objective quantification of SSc disease severity. Using transcriptome data from the largest longitudinal trial of SSc patients to date, they showed that 4S allowed them to objectively monitor individual SSc patients over time. The 4S test applied to the preexisting set of patient data could distinguish patients who were improving from those who were not 12 months after their treatment began. In contrast, the doctors' skin pinch test from the same set of data took 24 months to identify, which patients were improving. The study also uncovered a gene-activity signal suggesting the involvement of epidermal growth factor receptors in the disease.

Purvesh Khatri, PhD, assistant professor of medicine and a senior author of the study, “The data for all the healthy skin fell within one bubble, while all the data for the scleroderma patients fell within another and what was really cool was that we could predict on an individual level which patients would get better or worse.” The study was published on December 22, 2016, in the journal JCI Insight.

Related Links:
Stanford University School of Medicine


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.